Skip to content

Clinical and Immunological Categorization of Pulmonary Aspergillosis in Cystic Fibrosis

Clinical and Immunological Categorization of Pulmonary Aspergillosis in Cystic Fibrosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00012862
Enrollment
200
Registered
2017-09-04
Start date
2017-01-19
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E84 B44

Interventions

Group 1: We will screen patients with CF and will enroll eligible patients after written consent in this prospective cohort study. A medical history questionnaire will be completed and patient sampl
T-cell reactivity of the fungal proteins - lung function: FEV1, FVC and MEF25

Sponsors

Charite Universitätsmedizin Berlin
Lead Sponsor

Eligibility

Sex/Gender
All
Age
6 Years to 70 Years

Inclusion criteria

Inclusion criteria: -Provide written informed consent - Confirmed diagnosis of CF - Aged between 6 and 70 years - Ability to do a lung function test and to provide sputum samples for microbiological evaluation

Exclusion criteria

Exclusion criteria: Participants will not be entered in the study for any of the following exclusion criteria: - Patients unable to sign informed consent or unwilling to comply with the procedural requirements of this clinical protocol. - No ability to do a lung function test and to provide sputum samples for microbiological evaluation. - Not possible to take blood

Design outcomes

Primary

MeasureTime frame
Clinical confirmation of 6 distinct pulmonary aspergillosis stages: 1)Af Colonization 2)Af Sensitization1) 3)Non-allergic bronchopulmonary aspergillosis (Af bronchitis) 4)Allergic bronchopulmonary aspergillosis (ABPA) 5)Invasive pulmonary aspergillosis (Af-pneumonia) 6)Aspergilloma (chronic pulmonary aspergillosis)

Secondary

MeasureTime frame
- Lung function changes based on each of the above mentioned aspergillosis stages - Validated new biomarker(s) indicative for 1) Af Colonization: Af in sputum, qPCR 2) Af Sensitization: Af specific IgG and IgE, Galctomannan Index. 3) Af bronchitis: qPCR in sputum, no increased IgE 4) ABPA: total IgE, Af specific IgE, sputum, Galactomannan Index. 5) Af-pneumonia: T-cell reactivity of the fungal proteins 6) Aspergilloma: sputum, radiological imaging - Characterization of pathogen-Af interaction

Countries

Germany

Contacts

Public ContactCarsten Schwarz

Charité Universitätsmedizin BerlinKlinik für Pädiatrie m.S. Pneumologie und Immunologie Christiane Herzog Zentrum Berlin

carsten.schwarz@charite.de004930450666576

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 23, 2026